Enterome’s lymphoma drug wins FDA fast track designation The company is exploring EO2463’s efficacy in relapsed or refractory settings in a Phase I/II trial, with plans to start Phase III registrational trial in a “watch-and-wait” iNHL patient population

Enterome’s OncoMimics immunotherapy EO2463 gains FDA Fast Track for follicular lymphoma, paving the way for Phase III trials in in the low-tumor-burden “watch-and-wait” setting.

#News #Lymphoma #FDAfasttrack #CancerResearch #Enterome #Oncology

Enterome’s lymphoma drug wins FDA fast track designation The company is exploring EO2463’s efficacy in relapsed or refractory settings in a Phase I/II trial, with plans to start Phase III registrational trial in a “watch-and-wait” iNHL patient population

Enterome’s OncoMimics immunotherapy EO2463 gains FDA Fast Track for follicular lymphoma, paving the way for Phase III trials in in the low-tumor-burden “watch-and-wait” setting.

#News #Lymphoma #FDAfasttrack #CancerResearch #Enterome #Oncology

Quand les géants de la malbouffe financent nos médicaments Les géants de l’agroalimentaire vendent des aliments ultratransformés, tout en investissant dans des entreprises pharmaceutiques ou spécialisées dans la perte de poids. Un marché très lucratif.

Tout est lié ...

Quand les géants de la #malbouffe financent nos #médicaments

reporterre.net/Quand-les-ge...

#agroalimentaire #Nestlé #Danone #Unilever #Ummino #Wonderbelly #Actimel #Activia #HealthifyMe #Enterome #MicrobiomeDiagnosticsPartner #NestléHealthScience #HansJuergenWoerle